Increased intracellular phosphoribosylpyrophosphate and accelerated orotic acid decarboxylation in a mouse cell line resistant to purine and pyrimidine ribonucleosides.
A line of mouse fibroblasts (A9AU-1), originally selected for growth in the presence of 6-azauridine, has been found to be resistant to cytotoxic concentrations of adenosine, guanosine, and thymidine. A9AU-1 cells convert orotic acid to uridine 5'-monophosphate at twice the rate of the A9P line from which the A9AU-1 clone was selected. The resistant cells also excrete purines, synthesized de novo, into the medium at an increased velocity. The average intracellular 5-phosphoribosyl-1-pyrophosphate (PRPP) concentration of the resistant line is 45% higher than that of the parental line. The elevated PRPP concentration is likely to be responsible for both the apparent acceleration of pyrimidine synthesis and the increased excretion of purines into the growth medium; it might also account, by one of the several possible mechanisms, for the resistance of the cells to cytotoxic concentrations of the various nucleosides.
D000228:Adenine Phosphoribosyltransferase / Q000378:metabolism; D002460:Cell Line; D007041:Hypoxanthine Phosphoribosyltransferase / Q000378:metabolism; D009963:Orotic Acid / Q000378:metabolism*; D009964:Orotidine-5'-Phosphate Decarboxylase / Q000378:metabolism; D010428:Pentosephosphates / Q000378:metabolism*; D010754:Phosphoribosyl Pyrophosphate / Q000378:metabolism*; D011683:Purine-Nucleoside Phosphorylase / Q000378:metabolism; D012263:Ribonucleosides / Q000494:pharmacology*; D014541:Uridine Kinase / Q000378:metabolism
D010428:Pentosephosphates; D012263:Ribonucleosides; D009963:Orotic Acid; D010754:Phosphoribosyl Pyrophosphate; D011683:Purine-Nucleoside Phosphorylase; D000228:Adenine Phosphoribosyltransferase; D007041:Hypoxanthine Phosphoribosyltransferase; D014541:Uridine Kinase; D009964:Orotidine-5'-Phosphate Decarboxylase